Member Info for sadoldgit

Good constructive posts this morning from all.

0.7 million in tax credits that you had bought to the table Damion very pertinent.

So circa 3 million in the coffers.

Regards to all

Good morning Lazarus2

As much as l.understand that informal discussions are that and nothing else, informal discussions must lead to decisions being made by Sareum ie which route they take.

As yet we have not received the crucial phase1a data and to this importantly neither have interested parties.

Recent RNS's lack clarification as with mention of their intent. Phase 2a to enter into is costly but will carry more weight than phase 1a.

Do we have current finance ability to enter phase2a?

Why have a recent change of direction from 1a to 2a if not a result of informal discussion?

To enter into phase 2 is a considerable milestone achievement that will add value to 1801.

Of course cannot enter Phase 2a until full satisfactory results achieved.

Regards

Are we on the submission of phase1a data results to interested party or parties expecting a formal offer or offers to be made?

The continuation of development of SDC1802 indicated in the RNS would suggest along the lines of the above.

Open to discussion here.

Regards

'Post period end, the Company is today announcing a conditional equity fundraise of up to £1.5m (before expenses), via the issue of a total of up to 15,000,000 new ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares") at a price of 10 pence per new Ordinary Share (the "Placing Price") (the "Fundraise").

From the above extract of Sareums recently released RNS questions arise.

The original target of 1.5 million to be raised by share equity has nearly been reached by WRAP offer, in this case are the company seeking to pursue the target of 1.5 million via share equity or still intent on raising 1.2 million pound by the issue of a further 12 million shares?

Are we going to continue in Oz with 1b or are we going to instigate phase2a trials and if so and where with an anticipated time scale?

How are we developing in discussions with interested parties, ie informal discussion at the moment leading to formal communications on receipt of phase 1a data?

Good evening Num4.

You can have the best product in the world but if it is not marketed correctly no one will ever know.

I have no doubts that 1801 in some areas will stand head and shoulders over most other kinase inhibitors out there at the current time.

Attention to detail yes.

Marketing? It is portrayed as an also ran.

It lacks vigour and let's face it the positive reports we do get are a little drab. Far from attention grabbing.

Good evening Num4.

Yes remember the event pretty well.

Sdc compounds. Similar albeit not identical compounds.

A patent was granted for one compound and there was difficulty in obtaining a patent in the other due to their similarity.

However it was granted as one was for use in immuno oncology and the other was cleverly patented for use in immunotherapy.

Interesting now as SDC1802 is now gaining patent protection in differing regions of the world with a patent protectecting it in its use for immuno therapy!

Clearly both compounds are good and who is to say that SDC1802 would not work better in IBD than 1801?

Regarding the MHRA a preclinical requirement prior to clinical trial application is that an MTD to be established.

As Tboth2 said many moons back it can be accepted without a maximum tolerated dose established as a threshold had been exceeded at 30 times treatment dose with no adverse effects

As Tim remarked in his interview with the smooth talking Aussie Andrew Scott.

'We have been unable to establish a maximum tolerated dose at 30 times and we mat need to go as high as 100 times,

'A nice problem to have 'said Tim and it may come back to bite us.

A well put together post you have compiled there Num4 l am entirely in agreement with that you have written.

Regards

Regards

Regards

Good evening C79

Top end Tyk2 Jak1 inhibitors will be worth a fortune.

No reason as yet as why we will not be best in Psoriasis and one or 2 other Indications.

There will exist companies that will want it for next to nothing.

Regards

Potnak l have increased my holding by around 25% by using WRAP.

Funds need to be raised.

The offer was 30% percent below current market value at the time.

I do congratulate myself, shares are cheap and in no way has it decimated the market cap as with the RF finance.

Tell me what other option the BoD has to raise funds.

Dilution has been going on since we had an original 800 million shares in old money years ago.

Money has been raised by various share placings since.

Regards

The extended WRAP has raised significant funds.

This must be a magnitude of order better than than pumping shares into RF finance shafting

Dilution is inevitable as funds are needed for further development. The BoD have added.

Much better to have funds with a tad more dilution than insufficient to complete phase 1a.

The Jan 2nd RNS was positive, today's RNS's both positive. The SP starts to climb and bang in come RF.

A deliberate suppression of the SP.

Who are they in bed with?

Regards

The already invested shareholder has raised £1.12 million

Somebody here did mention that he thought the WRAP would be over subscribed 4 times.

Volume 4,280,000 shares

I will go for 600k raised via WRAP

Clearly RF don't want the price to rise.

Correction 98% in advanced stage HGSOC@

Chk1 is pertinent to some cancers. Mutated p53 check point is up to 90% prevalent in advanced stage HGOC for which at the moment prognosis is not good

Regards

Ph came aboard and they managed to drop the price from just over 6p to just under 3p in a day.

Only been aboard a day or so.

No reason at all.

Price picked up slightly and settled over the next day or so.

That will be RF l would hazard a guess.

LJ

There will also be big pharmas that will not want us to succeed.

BMS will not be overly keen!

Regards

Pleased to hear the op went fine Warty.

No chasing the nurses around too much.

Regards